MENU
ALMS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Alumis (ALMS) Ownership - Who owns Alumis?
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
488.09M
P/E Ratio
0.14
Total Cash
486.32M
Projected Growth
N/A
Total Debt
38.78M
Revenue
20.06M
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
4.71
Total Debt/Equity
N/A
Revenue/Share
0.34 USD as % of share price
Fundamentals
ALMS
Capitalization
488M
P/E Ratio
0.14
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
486M
Total Cash/Share
4.71
Total Debt
38.8M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.34%
Revenue
20.1M
ROE
N/A
Book Value
485M
P/B Ratio
1.01
Cash Flow
N/A
Earnings
33.18
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
10K
Current Ratio
6.05
Current Revenue Per Employee
14489.13
Dividends Per Share - Security
N/A
EBITDA
-435.74M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-51.94
Shares Held By Institutions
178M
Shares Outstanding - Current
103M
Total Liabilities
126M
Total Volume MTD
N/A
Value
1
Gain YTD
-39.822
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information